Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

We’re back with our roundup of the most insightful studies of the year, from the power of brain breaks to groundbreaking ...

A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in ...

CAR-T was developed to wipe out hard-to-treat blood cancers. But the cells that go bad in leukemias and lymphomas — immune ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Extracellular vesicles (EVs) have rapidly emerged as one of the most promising frontiers in modern biology. These nano-sized messengers mediate communication between cells, tissues, and organs, ...

Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company developing precision medicines that modulate regulatory T cells (Tregs) to restore immune balance, today announced dosing of the ...

The Company recently announced that it would advance development of TZLS-501, a dual-action IL-6R monoclonal antibody targeting both membrane-bound and soluble forms of IL-6R. This decision was based ...

Knowing that naloxone works by stalling the µ-opioid receptor in an early, latent state suggests that molecules that can bind more tightly or more selectively to this form of the receptor could be ...

Researchers with the Arkansas Agricultural Experiment Station have identified genetic mechanisms in rice that can help ...

This important study describes a deep learning framework that analyzes single-cell RNA data to identify a tumor-agnostic gene signature associated with brain metastases. The identified signature ...

Billy is a Senior Features Author for Collider. Having written over 300 articles in just over a year, Billy regularly covers the biggest TV shows and films releasing while also analysing some of the ...